IGF1 and cancer: While uncovering antagonism between the β-arrestin isoforms in controlling IGF-1R downregulation, it was demonstrated that biasing the IGF system toward β-arrestin 2 decreases the viability and the metastatic potential of cancer cells and hence could be considered an effective therapeutic strategy (Figure 2) [98,99,182].